Effect of Cilostazol-Loaded PCL/PEG Nanocapsules on Abdominal Aortic Tunics and Lipid Profile of Wistar Rats

Pilatti, Luís Daniel Silva; Rodrigues, Ricardo; Nascimento, Núbia da Silva; Gomes, Mona Lisa Simionatto; Zanin, Sandra Maria Warumby; Farago, Paulo Vitor; Busato, César Roberto.
Braz. arch. biol. technol ; 63: e20200062, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1132243

Documentos relacionados

  1. Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.
  2. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
  3. Low-Dose Phosphodiesterase III Inhibitor Reduces the Vascular Amyloid Burden in Amyloid-ß Protein Precursor Transgenic Mice.
  4. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
  5. Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
  6. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase.
  7. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis.
  8. Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
  9. Perioperative Cardioprotection: General Mechanisms and Pharmacological Approaches.
  10. The effect of hemodilution by cardiopulmonary bypass on protein binding of olprinone.